Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-2.98% $52.82
America/New_York / 24 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 788.72 mill |
EPS: | -1.470 |
P/E: | -35.93 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 52.80 mill |
Avg Daily Volume: | 0.467 mill |
RATING 2024-04-24 |
---|
S- |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Buy | |
Return On Asset: | Strong Buy | |
DE: | Buy | |
P/E: | Strong Buy | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -35.93 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-6.11x |
Company: PE -35.93 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$64.01 (21.18%) $11.19 |
Date: 2024-04-25 |
Expected Trading Range (DAY) |
---|
$ 49.92 - 55.72 ( +/- 5.49%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Ware Olivia C | Sell | 9 402 | Stock Option (right to buy) |
2024-04-16 | Ware Olivia C | Buy | 9 402 | Common Stock |
2024-04-16 | Ware Olivia C | Sell | 6 790 | Common Stock |
2024-04-16 | Ware Olivia C | Sell | 2 612 | Common Stock |
2024-04-01 | Elghandour Rami | Sell | 14 919 | Common Stock |
INSIDER POWER |
---|
-47.13 |
Last 100 transactions |
Buy: 1 139 480 | Sell: 3 755 187 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $52.82 (-2.98% ) |
Volume | 0.292 mill |
Avg. Vol. | 0.467 mill |
% of Avg. Vol | 62.48 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $61.53 | N/A | Active |
---|
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.